AstraZeneca Inks R&D Deal With Ramaswamy's Roivant for Hush-Hush Indication Post author:Sam Post published:October 18, 2017 Post category:BioPharma Vivek Ramaswamy’s parent company, Roivant Sciences, inked a development deal with Astra. Source: BioSpace You Might Also Like What Brent Saunders Thinks About a Possible Allergan Breakup October 19, 2017 Oxford BioMedica Wins $105M Gene Therapy Contract From Bioverativ February 14, 2018 AbbVie’s Elagolix Hits Primary Endpoints for Uterine Fibroids February 20, 2018
